Skip to main content
Premium Trial:

Request an Annual Quote

LION Bioscience: Revenues Down by 25 Percent

NEW YORK, Oct. 21-Lion Bioscience expects its revenues for the year to fall by as much as 25 percent from last year's totals, the company said today. In a statement released this morning, CEO Friedrich von Bohlen blamed non-cash write-offs, a shift from in-house drug discovery, and the general malaise in the life sciences industry for the shortfall.


In a conference call, von Bohlen said that given current economic conditions, many customers were waiting for new product introductions before making purchases, lengthening the sales cycle.


"Not that people are not interested, but in part, they say, 'It's great guys, but let's wait until the new more shiny product is available,'" he said.


The company will "conduct a review of its strategic investments in privately held companies," the statement said, and expects to adjust the current  €10.6 million book value of its affiliates by as much as € 8.5 million.


Lion also said it expects to write off intangible assets and impaired goodwill of € 62.1 million in its second quarter due to its acquisition of Trega Biosciences and NetGenics.


In June, the company had predicted moderate revenue growth for its fiscal year ending March 31, 2003.


Lion still expects to break even by the fourth quarter of 2004. During the call, Chief Financial Officer Martin Hollenhorst said that expectation was still reasonable because Lion plans to introduce new products in the coming quarters and has instituted cost-saving measures expected to reduce spending by 20 to 25 percent.


For more information, see the statement.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.